InsidersTradesSigma
Total declarations
Companies
▲ Purchases (13 ops.)
▼ Sales (0 ops.)
Explore the detailed record of transactions filed by Galante Joseph C, Director. Insider active across 2 companies, notably Cumberland Pharmaceuticals INC. Aggregated, 17 filings have been logged. Total volume traded: €4k. The latest transaction was disclosed on 1 June 2022 (Acquisition). Regulator: SEC (Form 4). All data is openly available.
Declarations17 total
€14676 shares@ €1.92410.0002% mcap1.2% of flow
Common Stock
SEC:0001209191-22-040094:0·
Ideal exit: 26 Feb 2023 (T+270)
€14261 shares@ €2.33130.0002% mcap1.2% of flow
Common Stock
SEC:0001209191-22-035994:0·
Ideal exit: 27 Jan 2023 (T+270)
€14056 shares@ €2.50440.0002% mcap1.2% of flow
Common Stock
SEC:0001209191-22-027646:0·
Ideal exit: 9 Jan 2023 (T+270)
€2,3611,000 shares@ €2.36110.0029% mcap20.1% of flow
Common Stock
SEC:0001209191-22-026138:0·
€18,115201 shares@ €90.1219100.0% of flow
PNFP Common Stock
SEC:0001567619-22-006185:0·
€328142 shares@ €2.31040.0004% mcap7.3% of flow
Common Stock
SEC:0001209191-21-067899·
Ideal exit: 29 Jul 2022 (T+270)
€328142 shares@ €2.31040.0004% mcap2.8% of flow
Common Stock
SEC:0001209191-21-067899:0·
Ideal exit: 29 Jul 2022 (T+270)
€330142 shares@ €2.32410.0004% mcap7.4% of flow
Common Stock
SEC:0001209191-21-063235·
Ideal exit: 28 Jun 2022 (T+270)
€330142 shares@ €2.32410.0004% mcap2.8% of flow
Common Stock
SEC:0001209191-21-063235:0·
Ideal exit: 28 Jun 2022 (T+270)
€345142 shares@ €2.43220.0004% mcap7.7% of flow
Common Stock
SEC:0001209191-21-058530·
Ideal exit: 29 May 2022 (T+270)
€345142 shares@ €2.43220.0004% mcap2.9% of flow
Common Stock
SEC:0001209191-21-058530:0·
Ideal exit: 29 May 2022 (T+270)
€399142 shares@ €2.81270.0005% mcap8.9% of flow
Common Stock
SEC:0001209191-21-055485·
Ideal exit: 29 Apr 2022 (T+270)
€399142 shares@ €2.81270.0005% mcap3.4% of flow
Common Stock
SEC:0001209191-21-055485:0·
Ideal exit: 29 Apr 2022 (T+270)
€381142 shares@ €2.6840.0005% mcap8.5% of flow
Common Stock
SEC:0001209191-21-051441·
Ideal exit: 4 Apr 2022 (T+270)
€381142 shares@ €2.6840.0005% mcap3.2% of flow
Common Stock
SEC:0001209191-21-051441:0·
Ideal exit: 4 Apr 2022 (T+270)
€2,7061,000 shares@ €2.70550.0033% mcap23.0% of flow
Common Stock
SEC:0001209191-21-039932:0·
€2,7061,000 shares@ €2.70550.0033% mcap60.3% of flow
Common Stock
SEC:0001209191-21-039932·
17 of 17 declarations
About Galante Joseph C
Joseph C. Galante is an executive at Cumberland Pharmaceuticals Inc.
